Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE315.008.95 (+2.92 % )
PREV CLOSE (Rs.) 306.05
OPEN PRICE (Rs.) 305.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 230972
TODAY'S LOW / HIGH (Rs.)305.00 319.05
52 WK LOW / HIGH (Rs.)211.3 320.48
NSE315.05 8.95 (+2.92 % )
PREV CLOSE(Rs.) 306.10
OPEN PRICE (Rs.) 305.95
BID PRICE (QTY) 315.05 (494 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 6990659
TODAY'S LOW / HIGH(Rs.) 305.80 319.00
52 WK LOW / HIGH (Rs.)211.05 320.98

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.16
TTM EPS (Rs.) 3.44
P/E Ratio 91.48
Book Value (Rs.) 61.94
Face Value (Rs.) 5
MCap (Rs. in Mn) 378000.00
Price/Earning (TTM) 72.12
Price/Sales (TTM) 16.65
Price/Book (MRQ) 5.09
PAT Margin (%) 17.08
ROCE (%) 7.89
Incorporation Year : 1978

Management Info :

Kiran Mazumdar-Shaw - Chairman Kiran Mazumdar-Shaw - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 080 2808 2808

Website : www.biocon.com

Registrar's Details : KFIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
27Jan01-27-2020$USFDA completes PAI, GMP inspection at Biocon’s Bengaluru facility USFDA completes PAI, GMP ins

US Food and Drug Administration (USFDA) has completed Pre-Approval Inspection (PAI) and GMP inspection at Biocon’s API Manufacturing Facility at Bengaluru. At the conclusion of the inspection of the Bengaluru facility, which took place between January 20 and January 24, 2020, the agency issued a Form 483, with five observations.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

US Food and Drug Administration (USFDA) has completed Pre-Appro..
27Jan01-27-2020$Biocon informs about company updates Biocon informs about company

Biocon has informed that the US Food and Drug Administration (FDA) conducted a Pre-Approval Inspection (PAI) and GMP inspection of the API Manufacturing Facility of the Company. At the conclusion of the inspection of the Bengaluru facility, which took place between January 20 and January 24, 2020, the agency issued a Form 483, with five observations. It will respond to the FDA with a Corrective and Preventive Action Plan (CAPA) and are confident of addressing these observations expeditiously. It remains committed to global standards of Quality and Compliance.

The above information is a part of company's filings submitted to BSE.

Biocon has informed that the US Food and Drug Administration (F..
24Jan01-24-2020$Biocon reports 7% fall in Q3 consolidated net profit Biocon reports 7% fall in Q3

Biocon has reported results for third quarter ended December 31, 2019.

The company has reported a rise of 66.02% in its net profit at Rs 120.70 crore for the quarter under review as compared to Rs 72.70 crore for the same quarter in the previous year. Total income of the company increased by 15.46% at Rs 552.50 crore for Q3FY20 as compared Rs 478.50 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 6.63% in its net profit at Rs 202.80 crore for the quarter under review as compared to Rs 217.20 crore for the same quarter in the previous year. However, total income of the company increased by 13.89% at Rs 1783.90 crore for Q3FY20 as compared Rs 1566.40 crore for the corresponding quarter previous year.

Biocon has reported results for third quarter ended December 31..
22Jan01-22-2020$Biocon’s arm receives Rs 536 crore subscription money from Activ Pine LLP Biocon’s arm receives Rs 5

Biocon’s wholly owned subsidiary--- Biocon Biologics India (BBIL) has received the subscription money aggregating to Rs 536.25 crore from Activ Pine LLP (an affiliate of True North Fund VI LLP). Consequently, the Board of BBIL has approved the allotment of 50,25,463 equity shares of Rs 10 each at a price of Rs 1,067.07 per equity share (including a premium of Rs. 1,057.07 per equity share) to Activ Pine LLP. Earlier, Biocon, BBIL and Activ Pine LLP have executed a share subscription agreement and a shareholder agreement. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon’s wholly owned subsidiary--- Biocon Biologics India (B..
22Jan01-22-2020$Biocon inches up as its arm receives Rs 536 crore subscription money from Activ Pine LLP Biocon inches up as its arm

Biocon is currently trading at Rs. 295.00, up by 0.55 points or 0.19% from its previous closing of Rs. 294.45 on the BSE.

The scrip opened at Rs. 294.00 and has touched a high and low of Rs. 297.00 and Rs. 292.90 respectively. So far 23727 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 341.43 on 25-Jan-2019 and a 52 week low of Rs. 211.30 on 20-Aug-2019.

Last one week high and low of the scrip stood at Rs. 297.00 and Rs. 281.30 respectively. The current market cap of the company is Rs. 35388.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.

Biocon’s wholly owned subsidiary--- Biocon Biologics India (BBIL) has received the subscription money aggregating to Rs 536.25 crore from Activ Pine LLP (an affiliate of True North Fund VI LLP). Consequently, the Board of BBIL has approved the allotment of 50,25,463 equity shares of Rs 10 each at a price of Rs 1,067.07 per equity share (including a premium of Rs. 1,057.07 per equity share) to Activ Pine LLP. Earlier, Biocon, BBIL and Activ Pine LLP have executed a share subscription agreement and a shareholder agreement. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 295.00, up by 0.55 points or..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit12074927
Gross Profit 1578 5521
Operating Profit 12825031
Net Sales 501328847
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 7322.90 (2.05%)
M.Cap ( in Cr)
16865.09
Ajanta Pharma (BSE)
 1446.05 (10.03%)
M.Cap ( in Cr)
12618.42
Ipca Laboratories (BSE)
 1456.15 (3.43%)
M.Cap ( in Cr)
18398.76
Solara Active Pharma (BSE)
 680.25 (6.01%)
M.Cap ( in Cr)
1772.41
Alkem Laboratories (BSE)
 2657.75 (1.39%)
M.Cap ( in Cr)
31777.39
Shareholding Pattern More
PROMOTERS 60.67 %
MUTUAL FUNDS/UTI 3.76 %
NON-INSTITUTION 17.7 %
FI/BANKS/INSURANCE 1.33 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes